Table 3.

Pre-systemic therapy cognition by molecular sub-type among older patients with non-metastatic breast cancer

a. Mean (SE) adjusted baseline cognitive scores by molecular subtype
Mean scores	HR +, HER2−(n = 493)	HR +, HER2 + (n = 51)	HR−,HER2 + (n = 15)	HR−, PR−, HER2− (triple negative) (n = 56)	p-value1
Self-reported cognitive problems (FACT cog PCI)*	60.8 (0.7)	59.7 (1.6)	50.9 (2.8)	61.0 (1.5)	0.006
APE z-score **	− .296 (0.036)	− .237 (0.090)	− .350 (0.159)	− .197 (0.084)	0.621
LM z-score**	− .306 (0.045)	− .377 (0.112)	− .578 (0.199)	− .430 (0.104)	0.370
b. Mean rates of baseline cognitive impairment by molecular subtype
Percent impaired	HR +, HER2− (n = 460) (%)	HR +, HER2 + (n = 46) (%)	HR−, HER2 + (n = 14) (%)	HR−, PR−, HER2− (triple negative) (n = 53) (%)	p-value2
Self-reported cognitive problems (FACT cog PCI)*	19.4	28.3	35.7	18.9	0.245
APE domain**	17.2	15.7	20.0	10.7	0.636
LM domain**	14.2	7.8	13.3	23.2	0.150

Adjusted for age, race, site; p values based on ANCOVA

p-values based on Chi-square tests

^*Scores on the FACT-Cog perceived cognitive impairment scale range from 0 to 72, with higher scores represent better cognitive function. 3–5 point differences are considered clinically meaningful and a score of < 54 is considered impaired

^**Z-scores for neuropsychological tests within each domain range from − 3 to + 3, with a mean of 0. A positive score indicates better cognitive performance and a negative score reflects worse than average scores. Having one of the tests within the domain with a score of < 2SD from the mean or two tests < 1.5 SD from the mean are considered impairment